MRI-guided liposomes for targeted tandem chemotherapy and therapeutic response prediction

Acta Biomaterialia

Volumn 35, Issue , 2016, Pages 260-268

  Ren, Lili ^a   Chen, Shizhen ^a   Li, Haidong ^a   Zhang, Zhiying ^a   Zhong, Jianping ^a   Liu, Maili ^a   Zhou, Xin ^a  

^a Wuhan National Laboratory for Optoelectronics   (China)

Author keywords

Carboplatin; Liposome; Magnetic resonance imaging; Non small cell lung cancer; Paclitaxel

Indexed keywords

BIOLOGICAL ORGANS; CHEMOTHERAPY; COMPUTERIZED TOMOGRAPHY; CONTROLLED DRUG DELIVERY; DIAGNOSIS; DISEASES; DRUG DOSAGE; IMAGE ENHANCEMENT; LIPOSOMES; TARGETED DRUG DELIVERY; TUMORS;

BIODISTRIBUTIONS; CARBOPLATIN; CONTRAST AGENT; DRUG-RESISTANCE; IN-VIVO; LIPOSOMAL DRUG DELIVERY SYSTEMS; NON SMALL CELL LUNG CANCER; PACLITAXEL; REAL- TIME; THERANOSTICS;

MAGNETIC RESONANCE IMAGING;

CONTRAST MEDIUM; GADODIAMIDE; LIPOSOME; NANOPARTICLE; ANTINEOPLASTIC AGENT; CARBOPLATIN; GADOLINIUM PENTETATE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CIRCULATION TIME; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; IN VIVO STUDY; LIPOSOMAL DELIVERY; LUNG TUMOR; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TREATMENT RESPONSE; ANIMAL; BAGG ALBINO MOUSE; CELL DEATH; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL DEATH; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GADOLINIUM DTPA; HUMANS; LIPOSOMES; MAGNETIC RESONANCE IMAGING; MICE, INBRED BALB C; PACLITAXEL; TREATMENT OUTCOME;

EID: 84958231222     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2016.02.011     Document Type: Article

References (50)

1. E. Quoix, G. Zalcman, J.P. Oster, V. Westeel, E. Pichon, A. Lavolé, and et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomized, phase 3 trial Lancet 378 2011 1079 1088
2. N. Hanna, F.A. Shepherd, F.V. Fossella, J.R. Pereira, F. Marinis, J. Pawel, and et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J. Clin. Oncol. 22 2004 1589 1597
3. J.H. Schiller, D. Harrington, C.P. Belani, C. Langer, A. Sandler, J. Krook, and et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer New Engl. J. Med. 346 2002 92 98
4. Y. Ohe, Y. Ohashi, K. Kubota, T. Tamura, K. Nakagawa, S. Negoro, and et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan Ann. Oncol. 18 2007 317 323
5. K. Kelly, J. Crowley, P.A. Bunn, C.A. Presant, P.K. Grevstad, C.M. Moinpour, and et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a southwest oncology group trial J. Clin. Oncol. 19 2001 3210 3218
6. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, A. Dowlati, and et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer New Engl. J. Med. 355 2006 2542 2550
7. J. Mai, S. Song, M. Rui, D. Liu, Q. Ding, J. Peng, and et al. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells J. Control. Release 139 2009 174 181
8. Y. Wang, K. Zhou, G. Huang, C. Hensley, X. Huang, X. Ma, and et al. A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals Nat. Mater. 13 2014 204 212
9. X. Ma, J. Jia, R. Cao, X. Wang, and H. Fei Histidine-iridium(III) coordination-based peptide luminogenic cyclization and cyclo-RGD peptides for cancer-cell targeting J. Am. Chem. Soc. 136 2014 17734 17737
10. X.H. Peng, Y. Wang, D. Huang, Y. Wang, H.J. Shin, Z. Chen, and et al. Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles ACS Nano 5 2011 9480 9493
11. R.S. Herbst, G. Giaccone, J.H. Schiller, R.B. Natale, V. Miller, C. Manegold, and et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III Trial-INTACT 2 J. Clin. Oncol. 22 2004 785 794
12. G. Scagliotti, S. Novello, J. Pawel, M. Reck, J.R. Pereira, M. Thomas, and et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer J. Clin. Oncol. 28 2010 1835 1842
13. P. Saintigny Recent advances in non-small cell lung cancer biology and clinical management Discov. Med. 13 2012 287 297
14. M.W. Ndinguri, R. Solipuram, R.P. Gambrell, S. Aggarwal, and R.P. Hammer Peptide targeting of platinum anti-cancer drugs Bioconjugate Chem. 20 2009 1869 1878
15. U. Gergis, G. Roboz, T. Shore, E. Ritchie, S. Mayer, U. Wissa, and et al. A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia Biol. Blood Marrow Tr. 19 2013 1040 1045
16. P.G. Tardi, R.C. Gallagher, S. Johnstone, N. Harasym, M. Webb, M.B. Bally, and et al. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo BBA-Biomembranes 1768 2007 678 687
17. P.G. Tardi, N.D. Santos, T.O. Harasym, S.A. Johnstone, N. Zisman, A.W. Tsang, and et al. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo Mol. Cancer Ther. 8 2009 2266 2275
18. L. Ren, S. Chen, H. Li, Z. Zhang, C. Ye, M. Liu, and et al. MRI-visible liposome nanovehicles for potential tumor-targeted delivery of multimodal therapies Nanoscale 7 2015 12843 12850
19. N.V. Koshkina, J.C. Waldrep, L.E. Roberts, E. Golunski, S. Melton, and V. Knight Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model Clin. Cancer Res. 7 2001 3258 3262
20. S. Koudelka, and J. Turánek Liposomal paclitaxel formulations J. Control. Release 163 2012 322 334
21. P. Crosasso, M. Ceruti, P. Brusa, S. Arpicco, F. Dosio, and L. Cattel Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes J. Control. Release 63 2000 19 30
22. P. Ma, and R.J. Mumper Paclitaxel nano-delivery systems: a comprehensive review J. Nanomed. Nanotechnol. 4 2013 1 16
23. V.P. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discov. 4 2005 145 160
24. B. Baruah, and A. Surin Interaction of liposome-encapsulated cisplatin with biomolecules J. Biol. Inorg. Chem. 17 2012 899 910
25. G.P. Stathopoulos, D. Antoniou, J. Dimitroulis, P. Michalopoulou, A. Bastas, K. Marosis, and et al. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial Ann. Oncol. 21 2010 2227 2232
26. C.M. Lee, T. Tanaka, T. Murai, M. Kondo, J. Kimura, W. Su, and et al. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo Cancer Res. 62 2002 4282 4288
27. X. Wang, J. Zhou, Y. Wang, Z. Zhu, Y. Lu, Y. Wei, and et al. A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions Eur. J. Cancer 46 2010 1474 1480
28. A. Chaudhury, S. Das, R.M. Bunte, and G.N.C. Chiu Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft Int. J. Nanomed. 7 2012 739 751
29. S. Biswas, N.S. Dodwadkar, P.P. Deshpande, and V.P. Torchilin Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo J. Control. Release 159 2012 393 402
30. Y. Liu, and N. Zhang Gadolinium loaded nanoparticles in theranostic magnetic resonance imaging Biomaterials 33 2012 5363 5375
31. T. Tagami, W.D. Foltz, M.J. Ernsting, C.M. Lee, I.F. Tannock, J.P. May, and et al. MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome Biomaterials 32 2011 6570 6578
32. K. Na, S.A. Lee, S.H. Jung, and B.C. Shin Gadolinium-based cancer therapeutic liposomes for chemotherapeutics and diagnostics Colloid. Surface. B. 84 2011 82 87
33. E. Cittadino, M. Ferraretto, E. Torres, A. Maiocchi, B.J. Crielaard, T. Lammers, and et al. MRI evaluation of the antitumor activity of paramagnetic liposomes loaded with prednisolone phosphate Eur. J. Pharm. Sci. 45 2012 436 441
34. Y. Miura, T. Takenaka, K. Toh, S. Wu, H. Nishihara, M.R. Kano, and et al. Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier ACS Nano 7 2013 8583 8592
35. G.K. Seward, Y. Bai, N.S. Khan, and I.J. Dmochowski Cell-compatible, integrin-targeted cryptophane-129Xe NMR biosensors Chem. Sci. 2 2011 1103 1110
36. S. Xu, B.Z. Olenyuk, C.T. Okamoto, and S.F.H. Alvarez Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances Adv. Drug Deliver. Rev. 65 2013 121 138
37. Y. Katanasaka, T. Ishii, T. Asai, H. Naitou, N. Maeda, F. Koizumi, and et al. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78 Int. J. Cancer 127 2010 2685 2698
38. J. Du, W.L. Lu, X. Ying, Y. Liu, P. Du, W. Tian, and et al. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals Mol. Pharm. 6 2009 905 917
39. Y. Liu, W.L. Lu, J. Guo, J. Du, T. Li, J.W. Wu, and et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plusparthenolide stealthy liposomes J. Control. Release 129 2008 18 25
40. Y. Yoshizawa, K. Ogawara, A. Fushimi, S. Abe, K. Ishikawa, T. Araki, and et al. Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416 Mol. Pharm. 9 2012 3486 3494
41. V.P. Chekhonin, V.P. Baklaushev, G.M. Yusubalieva, A.E. Belorusova, M.V. Gulyaevd, E.B. Tsitrinc, and et al. Targeted delivery of liposomal nanocontainers to the peritumoral zone of glioma by means of monoclonal antibodies against GFAP and the extracellular loop of Cx43 Nanomed. Nanotechnol. 8 2012 63 70
42. S. Kaida, H. Cabral, M. Kumagai, A. Kishimura, Y. Terada, M. Sekino, and et al. Visible drug delivery by supramolecular nanocarriers directing to single-platformed diagnosis and therapy of pancreatic tumor model Cancer Res. 70 2010 7031 7041
43. M. Hossann, T. Wang, Z. Syunyaeva, M. Wiggenhorn, A. Zengerle, R.D. Issels, and et al. Non-ionic Gd-based MRI contrast agents are optimal for encapsulation into phosphatidyldiglycerol-based thermosensitive liposomes J. Control. Release 166 2013 22 29
44. G. Mikhaylov, U. Mikac, A.A. Magaeva, V.I. Itin, E.P. Naiden, I. Psakhye, and et al. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment Nat. Nanotechnol. 6 2011 594 602
45. S. Meng, B. Su, W. Li, Y. Ding, L. Tang, W. Zhou, and et al. Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes Nanotechnology 21 2010 1 7
46. P.P. Shah, M.Y. Fong, and S.S. Kakar PTTG induces EMT through integrin AlphaV Beta3-focal adhesion kinase signaling in lung cancer cells Oncogene 31 2012 3124 3135
47. R. Yao, A. Sui, Z. Wang, S. Liu, Q. Zhou, X. Liu, and et al. Induction of non-small cell lung carcinoma apoptosis using soluble RGD-TRAIL by targeting the integrin receptor of tumor cells Mol. Med. Rep. 6 2012 1355 1360
48. J.S. Desgrosellier, and D.A. Cheresh Integrins in cancer: biological implications and therapeutic opportunities Nat. Rev. Cancer 10 2010 9 22
49. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D.C. Pearson, R.A. Burger, and et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study J. Clin. Oncol. 21 2003 3194 3200
50. P.A. Vasey, G.C. Jayson, A. Gordon, H. Gabra, R. Coleman, R. Atkinson, and et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma J. Natl. Cancer I. 96 2004 1682 1691